Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 17/20 | 0.72 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LIFR | P42702 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428382 | 0.80 | NR1H4 (0.62) | NR1H4LIFR | |
| SCHEMBL4835425 | 0.79 | NR1H4 (0.61) | NR1H4LIFR | |
| SCHEMBL4598944 | 0.76 | NR1H4 (0.87) | NR1H4LIFRPPARD | |
| SCHEMBL30412532 | 0.73 | NR4A2 (0.74) | NR1H4NR4A2NR4A1NR4A3NPC1 | |
| SCHEMBL978508 | 0.73 | NR4A2 (0.74) | NR1H4NR4A2NR4A1NR4A3NPC1 | |
| SCHEMBL5838953 | 0.71 | NR4A2 (1.00) | NR4A2NR4A1NR4A3NPC1RAB9A | |
| SCHEMBL4426866 | 0.70 | NR1H4 (0.86) | NR1H4LIFRPPARD | |
| SCHEMBL4838231 | 0.69 | NR1H4 (0.85) | NR1H4LIFRPPARD | |
| SCHEMBL4831063 | 0.69 | NR1H4 (0.59) | NR1H4LIFR | |
| SCHEMBL4950788 | 0.68 | NR1H4 (0.61) | NR1H4LIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | claimed |
| US-20060258725-A1 | Farnesoid x receptor agonists | SMITHKLINE BEECHAM CORPORATION | 2006-11-16 | — | — | US | claimed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008039829-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-1885694-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | Microbia, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877067-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1877373-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258725-A1 | Farnesoid x receptor agonists | SMITHKLINE BEECHAM CORPORATION | 2006-11-16 | — | — | US | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006116499-A1 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA | MICROBIA, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1562915-A1 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004048349-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | NR1H4 24/4885NR4A2 1038/4885NR4A1 875/4885 |
| US-20060258725-A1 | Farnesoid x receptor agonists | NR1H4, GPBAR1, NR1H2 | NR1H4 1/4885NR4A2 329/4885NR4A1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.